MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.1 USD | +0.31% |
|
-1.32% | +18.02% |
| May. 14 | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
| May. 13 | Merck: phase 3 trial in melanoma halted | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 64.11B | Sales 2025 * | 68.6B | Capitalization | 326B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B | Net income 2025 * | 22.27B | EV / Sales 2024 * | 5.38 x |
| Net Debt 2024 * | 18.91B | Net Debt 2025 * | 7.6B | EV / Sales 2025 * | 4.86 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.4
x | Employees | 71,000 |
| Yield 2024 * |
2.41% | Yield 2025 * |
2.54% | Free-Float | 70.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
| 1 day | +1.43% | ||
| 1 week | -1.32% | ||
| Current month | -0.43% | ||
| 1 month | +2.32% | ||
| 3 months | +2.26% | ||
| 6 months | +25.93% | ||
| Current year | +18.02% |
1 week
128.02
130.88
1 month
124.50132.80
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 254 M€ | +10.27% | - | |
| 5.61% | 17 M€ | +7.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 128.7 | -0.49% | 6 154 340 |
| 24-05-13 | 129.3 | -0.59% | 7,109,912 |
| 24-05-10 | 130.1 | -0.13% | 5,722,627 |
| 24-05-09 | 130.2 | +0.52% | 9,216,740 |
| 24-05-08 | 129.6 | -0.64% | 6,659,121 |
Delayed Quote Nyse, May 14, 2024 at 04:00 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
128.7
USD
Average target price
141.6
USD
Spread / Average Target
+10.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.02% | 326B | |
| +30.96% | 588B | |
| -3.42% | 364B | |
| +4.27% | 285B | |
| +14.79% | 239B | |
| +10.12% | 210B | |
| -6.99% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B | |
| +1.50% | 124B |
- Stock Market
- Equities
- MRK Stock
